Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.

Micol FerraraJessica CusatoElena SalvadorAlice TrentalangeChiara AlcantariniMattia TrunfioElvira Stefania CannizzoValeria BonoSilvia NozzaAmedeo De NicolòAlice IannielloElisa De VivoAntonio D'AvolioGiovanni Di PerriStefano BonoraGiulia MarchettiAndrea Calcagno

Published in: British journal of clinical pharmacology (2022)

Our preliminary data support the hypothesis of lower DRV and DTG IC concentrations and lower TFV plasma exposure in patients with higher plasma IM suggesting an interplay between HIV drug penetration and persistent inflammation in cART-treated HIV-positive patients.

Keyphrases

hiv positive
antiretroviral therapy
hiv infected patients
hiv infected
men who have sex with men
human immunodeficiency virus
south africa
hiv aids
oxidative stress
newly diagnosed
end stage renal disease
hiv testing
ejection fraction
electronic health record
hepatitis c virus
machine learning